ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2310건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1610 | Recruiting | COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research | Immune Checkpoint Inhibitor | Biological: Any Chinese government-recommended COVID-19 booster vaccine | Not Applicable | Peking Union Medical College Hospital | OTHER | 1224 | All | 18 Years | Peking Union Medical College Hospital, Peking, China |
| 1609 | Withdrawn | COVID-19 Vaccine For Indirect Protection | Vaccine Preventable Disease | Biological: COVID-19 Vaccination Other: Usual care |
Phase 4 | McMaster University, University of Alberta, University of Saskatchewan, University of Manitoba | OTHER | 0 | All | McMaster University, Hamilton, Ontario, Canada | |
| 1608 | Completed | COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases | SLE | Biological: Moderna COVID-19 vaccine | Phase 3 | McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Ministere de la Sante et des Services Sociaux | OTHER | 220 | All | 18 Years | McGill University Health Centre, Montreal, Quebec, Canada |
| 1607 | Unknown status | COVID-19 VACCINE SAFETY AND EFFECTIVENESS | SARS-CoV-2 Infection | Biological: ChAdOx1 nCoV-19 vaccine (AZD1222) | Phase 2 | Federal University of Espirito Santo, Centro de Pesquisas Rene Rachou | OTHER | 550 | All | 18 Years | Federal University of Espirito Santo, Vitoria, Espirito Santo, Brazil |
| 1606 | Recruiting | COVID-19 Vaccines in Patients With Chronic Liver Disease | Liver Disease Chronic | Biological: COVID-19 Vaccines | Not Applicable | Beijing 302 Hospital | OTHER | 300 | All | 18 Years | The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China |
| 1605 | Completed | COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) | COVID-19 | Drug: AS03 Biological: BNT162b2 Biological: BNT162b2 (B.1.1.529) Biological: BNT162b2 (B.1.351) Biological: BNT162b2 bivalent (wildtype and Omicron BA.1) Biological: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) Biological: CoV2 preS dTM [B.1.351] Biological: CoV2 preS dTM/D614 Biological: CoV2 preS dTM/D614+B.1.351 Biological: mRNA-1273 Biological: mRNA-1273.351 Biological: mRNA-1273.529 Biological: mRNA-1273.617.2 Other: Sodium Chloride, 0.9% |
Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 1270 | All | 18 Years | University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama, United States University of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States Zuckerberg San Francisco General Hospital, UCSF Positive Health Program, San Francisco, California, United States George Washington University Medical Faculty Associates, Washington, District of Columbia, United States Howard University - Department of Medicine - Division of Infectious Disease, Washington, District of Columbia, United States Morehouse School of Medicine - Clinical Research Center, Atlanta, Georgia, United States Emory University School of Medicine, Atlanta, Georgia, United States The Hope Clinic of Emory University, Decatur, Georgia, United States University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States Tulane University Clinical Translational Unit, New Orleans, Louisiana, United States Brigham and Women's Hospital, Boston, Massachusetts, United States Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States NYU Grossman School, NYU Langone Vaccine Center, Long Island, Mineola, New York, United States NYU Langone Vaccine Center Research Clinic, Manhattan, New York, New York, United States University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States Duke Vaccine and Trials Unit, Durham, North Carolina, United States Baylor College of Medicine, Houston, Texas, United States University of Texas Medical Branch, League City, Texas, United States Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States The University of Washington - Virology Research Clinic, Seattle, Washington, United States |
| 1604 | Completed | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | Chronic Lymphocytic Leukemia | Drug: A single "booster" dose of the Moderna mRNA COVID-19 vaccine | Phase 2 | Barbara Ann Karmanos Cancer Institute | OTHER | 119 | All | 18 Years | Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States |
